Enprostil and Ranitidine in Duodenal Ulcer Healing: Double Blind Comparative Trial

One hundred and eighty patients with endoscopically proved duodenal ulcers were allocated at random to double blind treatment with the synthetic dehydroprostaglandin E2 enprostil 35 µg twice daily or ranitidine 150 mg twice daily for up to six weeks. Patients completed the study if ulcer healing and pain relief had occurred at two or four weeks. A total of 163 patients completed the trial. The duration of treatment was longer in the enprostil group (p<0·005) and the cumulative healing rates at two, four, and six weeks were 51%, 74%, and 85%, respectively. In the ranitidine group the corresponding figures were 65% (p<0·04), 89% (p<0·02), and 99% (p<0•002). More patients treated with ranitidine reported relief of pain (p<0·004 at weeks 5 and 6). The observed superiority of ranitidine 150 mg twice daily over enprostil 35 µg twice daily questions the clinical relevance of using so called “cytoprotection” as treatment for duodenal ulcer disease in the short term.